

# DRUG INTERACTIONS

Drug	Proposed mechanism	Intervention
Cyclosporine	CYP3A4/P-gp Inhibitor and CYP3A4 Substrate (Decreases metabolism and increases blood concentration of everolimus)	Consider therapy modification. (Any dose modification to cyclosporine will require dose modification to everolimus)
Ketoconazole	Strong CYP3A4 Inhibitor	Avoid combination
Erythromycin	Moderate CYP3A4 Inhibitor	Consider therapy modification Everolimus blood concentrations should be monitored and a dose adjustment made as necessary.
Verapamil	CYP3A4 and P-gp Substrate	Consider therapy modification Everolimus blood concentrations should be monitored and a dose adjustment made as necessary.
Atorvastatin and Pravastatin	Atorvastatin (CYP3A4 Substrate), Pravastatin (P-gp Substrate) Interact with cyclosporine (they are substrates of CYP3A4)	Minor risk Patients should be monitored for the development of rhabdomyolysis and other adverse events. strongly discouraged
Simvastatin and Lovastatin	Interact with cyclosporine (they are substrates of CYP3A4)	strongly discouraged
Rifampin	Strong CYP3A4 Inducers (Increases metabolism and Decreases blood concentration of everolimus)	Consider therapy modification
(fluconazole; macrolide antibiotics; nifedipine, diltiazem; nelfinavir, indinavir, amprenavir)	Moderate CYP3A4 Inhibitors	-
St. John's Wort [Hypericum perforatum]; anticonvulsants: carbamazepine, phenobarbital, phenytoin; efavirenz, nevirapine)	Moderate CYP3A4 inducers	- 